Yaara Ofir-Rosenfeld

Yaara Ofir-Rosenfeld

Company: STORM Therapeutics Ltd.

Job title: Director, Translational Oncology


Inhibition of METTL3 Activates Innate Immunity Pathways & Reshapes the Tumor Microenvironment 3:30 pm

STC-15 is a potent and selective inhibitor of the RNA methyltransferase METTL3, currently evaluated in a First-in-Human Phase I clinical trial STC-15 leads to formation of dsRNA and induces cancer intrinsic type-I interferon response Ex-vivo and in-vivo efficacy studies in preclinical models demonstrate an immune based MoA leading to a long term tumour regression and…Read more

day: Conference Day 1

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.